GLP1R and Obesity: In brief, it appears that combinatorial unimolecular therapies, which incorporate GLP‐1 receptor benefits together with the metabolic advantages of other related gastrointestinal tract‐derived hormones, have unmistakeable therapeutic potential for obesity, diabetes and beyond.